“We are not disclosing the (exact) valuation, but it is sub-$3 billion,” said Tu. In March, Prosus had valued Byju’s at about $5.1 billion. It holds a stake of nearly 10% in the troubled edtech firm.
Elevate Your Tech Prowess with High-Value Skill Courses
| Offering College | Course | Website |
|---|---|---|
| Indian School of Business | ISB Product Management | Visit |
| Northwestern University | Kellogg Post Graduate Certificate in Product Management | Visit |
| IIT Delhi | IITD Certificate Programme in Data Science & Machine Learning | Visit |
Late last year, Prosus said it had ceased equity accounting of Byju’s as it had lost “significant influence” over the firm after its holding slipped below 10%.
“We are in close discussions with the company every day. Byju’s is faced with multiple challenges,” Tu said, responding to a question on the edtech company.
Prosus listed Byju’s among India portfolio firms that were “large underperformers” impacting its internal rate of return (IRR). Others on the list include PharmEasy.
ET reported on November 29 that Byju’s top shareholders have demanded the company meet certain conditions before they consider any future capital infusion into the beleaguered edtech firm, which is battling a deepening fund crunch. The investors have asked the company to file its audited financials for the year ended March 31, 2023 at the earliest. In addition, they want founder Byju Raveendran to loosen his day-to-day control over operations, the sources added.
Discover the stories of your interest
Meanwhile, furthering his role as a white knight to the Bengaluru company, Manipal Education and Medical Group chairman Ranjan Pai extended around Rs 250-270 crore in fresh funding to Byju’s a few weeks back, according to the people cited above.